Podcasts about taofeek

  • 13PODCASTS
  • 55EPISODES
  • 46mAVG DURATION
  • 1WEEKLY EPISODE
  • Mar 26, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about taofeek

Latest podcast episodes about taofeek

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 26, 2024 53:11


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 26, 2024 53:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Internal Medicine CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 26, 2024 53:11


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 26, 2024 53:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 26, 2024 53:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Clinical Pharmacology CME/CNE/CPE Video
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 26, 2024 53:11


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 26, 2024 53:11


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 26, 2024 53:08


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy change phd transition patients md consultants pfizer advisor optimizing clinic astrazeneca accelerating therapies md phd medical education sanofi catalysts genentech glaxosmithkline abbvie bristol myers squibb gilead sciences planning committee sclc accreditation council janssen pharmaceuticals flatiron health jazz pharmaceuticals daiichi sankyo emd serono pvi emerging strategies fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe eisai inc practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall takeda pharmaceutical company limited cardiff oncology inspirna g1 therapeutics cme moc aapa ipce owonikoko taofeek turning point therapeutics hoffmann la roche ltd genentech
The Nigerian Scam
32. A Nigerian Communist in Vietnam

The Nigerian Scam

Play Episode Listen Later Mar 7, 2024 100:18


In our latest episode, we examine the Vietnamese socialist project in a lighthearted conversation with Taofeek ( @afolxbi ), a young Nigerian communist who visited recently. Amongst the many things we looked to learn, we were curious to know if and/or how, decades after their protracted civil war, a 'unified' Vietnam is moving on. We also covered issues around attitudes towards (economic) development outside of the cities. The Vietnamese lesson (hammers & sickles), as you might find, is that an engaged citizenry is a vital component of nation building

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 12, 2024 52:14


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 12, 2024 52:14


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 12, 2024 52:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Clinical Pharmacology CME/CNE/CPE Video
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 12, 2024 52:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 12, 2024 52:14


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Internal Medicine CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 12, 2024 52:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 12, 2024 52:14


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 12, 2024 52:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

university power phd research ms current progress patients md consultants pfizer advisor clinical harnessing astrazeneca advances accelerate md phd medical education axiom genentech bristol myers squibb patient outcomes planning committee sclc accreditation council natera janssen pharmaceuticals flatiron health emerging therapies jazz pharmaceuticals daiichi sankyo emd serono incyte pvi fasco continuing medical education accme abbvie inc bayer corporation pharmacy education acpe pharmamar biontech se eisai inc mirati therapeutics practice aids peerview institute reviewer disclosuresplanners grant research support disclosure policyall data safety monitoring board takeda pharmaceutical company limited g1 therapeutics cardiff oncology iteos therapeutics cme moc aapa owonikoko ipsen pharma taofeek turning point therapeutics hoffmann la roche ltd genentech
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 30, 2023 83:14


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 30, 2023 83:20


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 30, 2023 83:20


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 30, 2023 83:14


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 30, 2023 83:20


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 30, 2023 83:14


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 30, 2023 83:20


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 30, 2023 83:14


Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 28, 2022 61:16


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 61:09


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 61:09


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 61:09


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Clinical Pharmacology CME/CNE/CPE Video
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 28, 2022 61:16


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 28, 2022 61:16


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 61:09


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 28, 2022 61:16


Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

Trikkeligaen
Episode 4 - Lobben til Taofeek. Og Spell til Ivan, Christian!

Trikkeligaen

Play Episode Listen Later Oct 28, 2020 55:37


På tide å teste ut noen spalter, eller? Hva er ukas verste og beste øyeblikk i Oslo-fotballen? Og hva har egentlig skjedd på omtrent denne dag for omtrent 40 år sida? Reidar Sollie, Pål Karstensen og Aslak Borgersrud rekker også innom Vålerenga mot Kristiansund, Skeid mot Kvik Halden, opprykkskandidatene i tredje divisjon, og hvilken Oslo-bane som er best på det aller viktigste. Hosted on Acast. See acast.com/privacy for more information.

acast oslo spell hva kristiansund skeid aslak borgersrud taofeek
GRACEcast
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko

GRACEcast

Play Episode Listen Later Jan 3, 2016 28:15


Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

university cancer institute patients resistance forum horn drs vanderbilt ingram lung acquired alk nsclc winship panel q ros1 rearrangement gracecast cancergrace acquired resistance leora horn owonikoko taofeek nonsmall taofeek owonikoko freemandaily
GRACEcast ALL Subjects audio and video
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 3, 2016 28:15


Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

university cancer institute patients resistance forum horn drs vanderbilt ingram lung acquired alk nsclc winship panel q ros1 rearrangement gracecast cancergrace acquired resistance leora horn owonikoko taofeek nonsmall taofeek owonikoko freemandaily
GRACEcast Lung Cancer Video
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 3, 2016 28:15


Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

university cancer institute patients resistance forum horn drs vanderbilt ingram lung acquired alk nsclc winship panel q ros1 rearrangement gracecast cancergrace acquired resistance leora horn owonikoko taofeek nonsmall taofeek owonikoko freemandaily
GRACEcast Lung Cancer Video
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 1, 2016 31:43


Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

university cancer institute patients resistance forum lung acquired new ideas treatment options alk nsclc winship ros1 rearrangement gracecast cancergrace acquired resistance crizotinib owonikoko alectinib taofeek nonsmall ceritinib xalkori alecensa brigatinib zykadia
GRACEcast
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACEcast

Play Episode Listen Later Jan 1, 2016 31:43


Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

university cancer institute patients resistance forum lung acquired new ideas treatment options alk nsclc winship ros1 rearrangement gracecast cancergrace acquired resistance crizotinib owonikoko alectinib taofeek nonsmall ceritinib xalkori alecensa brigatinib zykadia
GRACEcast ALL Subjects audio and video
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 1, 2016 31:43


Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

university cancer institute patients resistance forum lung acquired new ideas treatment options alk nsclc winship ros1 rearrangement gracecast cancergrace acquired resistance crizotinib owonikoko alectinib taofeek nonsmall ceritinib xalkori alecensa brigatinib zykadia
GRACEcast ALL Subjects audio and video
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 16, 2015 36:39


Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

university west cancer institute patients resistance forum drs lung mutation acquired egfr alk nsclc winship panel q rearrangement gracecast cancergrace acquired resistance owonikoko taofeek reckamp nonsmall taofeek owonikoko
GRACEcast Lung Cancer Video
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 16, 2015 36:39


Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

university west cancer institute patients resistance forum drs lung mutation acquired egfr alk nsclc winship panel q rearrangement gracecast cancergrace acquired resistance owonikoko taofeek reckamp nonsmall taofeek owonikoko
GRACEcast
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

GRACEcast

Play Episode Listen Later Dec 16, 2015 36:39


Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

university west cancer institute patients resistance forum drs lung mutation acquired egfr alk nsclc winship panel q rearrangement gracecast cancergrace acquired resistance owonikoko taofeek reckamp nonsmall taofeek owonikoko
GRACEcast ALL Subjects audio and video
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 11, 2015 23:55


Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

GRACEcast Lung Cancer Video
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 11, 2015 23:55


Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

GRACEcast
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases

GRACEcast

Play Episode Listen Later Dec 11, 2015 23:55


Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

GRACEcast Lung Cancer Video
Molecular Testing in Early Stage Non-Small Cell Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 18, 2014 3:51


Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014

GRACEcast ALL Subjects audio and video
Molecular Testing in Early Stage Non-Small Cell Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 18, 2014 3:51


Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014

GRACEcast
Molecular Testing in Early Stage Non-Small Cell Lung Cancer

GRACEcast

Play Episode Listen Later Sep 18, 2014 3:51


Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014

GRACEcast Lung Cancer Video
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 14, 2014 3:49


A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.

GRACEcast ALL Subjects audio and video
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 14, 2014 3:49


A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.

GRACEcast
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?

GRACEcast

Play Episode Listen Later Sep 14, 2014 3:49


A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.

GRACEcast ALL Subjects audio and video
Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 9, 2014 4:21


Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014

GRACEcast
Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?

GRACEcast

Play Episode Listen Later Sep 9, 2014 4:21


Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014

GRACEcast Lung Cancer Video
Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 9, 2014 4:21


Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014